CLINICAL EXPERIENCE OF USE OF BEVACIZUMAB (AVASTIN) IN PATIENTS WITH METASTATIC BREAST CANCER WITH UNIDENTIFIED HER2/NEW AND ER PR-RECEPTOR STATUS


Cite item

Full Text

Abstract

The large randomized phase III E2100, AVADO and RIBBON-1 trials have demonstrated high effectiveness of bevacizumab (Avastin) in first line treatment of advanced breast cancer (BC). This drug was effective as addition to the second line standard chemotherapy for metastatic breast cancer in RIBBON-2 study. Data for the use of this drug in routine clinical practice in patients with unexplained HER2/new and ER / PR-receptor status are limited, although these patients can be considered as candidates for the 1-st line and 2-nd line chemotherapy in combination with bevacizumab, because administration of bevacizumab does not require determining the VEGF (vascular endothelial growth factor) level and VGRF receptors. The article presents the experience of successful clinical use of bevacizumab with and without taxanes, in patients with metastatic breast cancer with unidentified (for one reason or another) HER2/new and ER/PR-receptor status.

References

  1. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-67.
  2. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008;26:suppl; abstr LBA1011.
  3. Robert NJ, Dieras V, Brufsky GA, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER-2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2009;27(15s):abstr 1005.
  4. Brufsky A, Bondarenko IN, Smirnov V, et al. RIBBON-2: A randomized, double-blind, placebo controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER-2-negative metastatic breast cancer. SABCS December 9-13, 2009:abstr. 42.
  5. O'Shaughnessy J, et al. J Clin Oncol 2010;28(15s)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies